Drug Profile

Research programme: JAK inhibitors - Ajax Therapeutics/Schrodinger

Latest Information Update: 23 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ajax Therapeutics
Developer Ajax Therapeutics; Schrodinger
Class Antineoplastics; Aza compounds; Benzimidazoles; Ethers; Small molecules
Mechanism of Action Janus kinase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Jul 2025 Ajax Therapeutics and Schrodinger expand research collaboration for JAK inhibitors
17 Jul 2025 Early research in Unspecified in USA (unspecified route) (Schrodinger pipeline, July 2025)
04 Nov 2022 Preclinical trials in Myeloproliferative disorders in USA (unspecified route) before November 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com